MobiHealth News January 13, 2022
The company also unveiled its 2021 revenue.
At the J.P. Morgan Healthcare Conference this week, Dexcom, maker of continuous glucose monitoring systems, made waves after CEO Kevin Sayers announced new clinical trial data from its yet to be released CGM, the G7.
The 308 person trial demonstrated that the G7’s mean absolute relative difference (MARD) was 8.2% for adults and 8.1% for pediatric patients. The G7 was submitted to the FDA in the fourth quarter of 2021 and is still awaiting regulatory clearance.
On the financial side, Sayers revealed the company is expected to make $2.448 billion in unaudited revenue for 2021, a 27% increase from 2020. In this upcoming year, the company forecasts that it will bring...
Today's Sponsors
Today's Sponsor